The Critical American Biotech Stock Fast-Tracked by the FDA

Because of the role they’re playing in helping solve Covid-19, this U.S. biotech firm was recently fast-tracked by the FDA… and given a rare “Emergency Use Authorization” (more info on this via the link below).

It provides the testing equipment researchers need to evaluate their different treatments for the coronavirus.

This equipment is used by over 10,000 research labs worldwide and that number is growing at a rapid pace.

But not only that – this company also has a brand-new model slated to come out in the fourth quarter!

It’s like whenever Apple releases a new iPhone. Share prices spike.

Same thing here – Every time this company introduced new models in the past… It has led to a massive influx in revenue and share price.

  • Back in 2007, when the company introduced its first model, shares rose 238%…
  • In 2009, it happened again. Shares tripled…
  • In 2012, same story again. Shares surged 365%…
  • And in 2017, shares rose another 189%.

So, it’s critical people take a position… Before the new model comes out.

Click here for the full details on the company and their technology, including how to get the ticker symbol before the next big release.

Don’t Stop Here

More To Explore

Market Brief: AI Risks and Fed Minutes Incoming

Market Snapshot Market Pulse: U.S. stocks edged sideways, buoyed by fresh AI chatter that kept tech afloat while industrial sectors shrugged off supply-chain jitters. Bond

AARD: 56% Drop Sparks Urgent Investor Scrutiny!

Overview: Aardvark Therapeutics, Inc. (Nasdaq: AARD) is a clinical-stage biotech focused on therapies for metabolic diseases and Prader-Willi Syndrome (PWS) – a rare genetic disorder

Gene-Editing Goldrush Meets AI and ETF Plays

Opening Recap Market Pulse: Gene-editing fervor rippled through biotech circles after a Mordor Intelligence report flagged double-digit growth in cell line development through 2031. Down